Main Outcome Measures
Abbreviations and Acronyms:AE ( adverse event), BBFC ( brinzolamide 1% and brimonidine 0.2% fixed combination), BCVA ( best-corrected visual acuity), BID ( 2 times per day), IOP ( intraocular pressure), ITT ( intent-to-treat), LS ( least squares), SAE ( serious adverse event), SD ( standard deviation), TID ( 3 times per day)
- Terminology and Guidelines for Glaucoma.3rd ed. Editrice DOGMA, Savona, Italy2008: 122-145 (Available at:)Accessed June 9, 2014)
- Intraocular pressure response to medication in a clinical setting: the Marshfield Clinic Personalized Medicine Research Project.J Glaucoma. 2008; 17: 372-377
- Treatment of glaucoma patients with insufficient intraocular pressure control: a survey of German ophthalmologists in private practice.Curr Med Res Opin. 2008; 24: 1295-1301
- A gap analysis approach to assess patient persistence with glaucoma medication.Am J Ophthalmol. 2007; 144: 520-524
- Glaucoma medication persistence with a fixed combination versus multiple bottles.Curr Med Res Opin. 2009; 25: 2543-2547
- Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study.Arch Ophthalmol. 2010; 128: 165-172
- Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%.JAMA Ophthalmol. 2013; 131: 724-730
- Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%/brimonidine 0.2%.J Ocul Pharmacol Ther. 2013; 29: 290-297
- Six-month results from a phase III randomized trial of fixed-combination brinzolamide 1% + brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension.Clin Ophthalmol. 2013; 7: 1053-1060
- Fixed-combination brinzolamide 1%/brimonidine 0.2% vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studies.Eye (Lond). 2013; 27: 841-847
- Patient satisfaction with topical ocular hypotensives.Clin Experiment Ophthalmol. 2013; 41: 27-35
- Patient-reported behavior and problems in using glaucoma medications.Ophthalmology. 2006; 113: 431-436
- Determinants of adherence to glaucoma medical therapy in a long-term patient population.J Glaucoma. 2009; 18: 238-243
- Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review.Ophthalmology. 2005; 112: 953-961
- Drop size and initial dosing frequency problems of topically applied ophthalmic drugs.J Pharm Sci. 1974; 63: 333-338
- Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication.Br J Ophthalmol. 2002; 86: 418-423
- Considerations in glaucoma therapy: fixed combinations versus their component medications.Clin Ophthalmol. 2010; 4: 1-9
- Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials.Ophthalmology. 2005; 112: 1177-1185
Supplemental material is available at www.aaojournal.org.
Financial Disclosure(s): The author(s) have made the following disclosure(s): T.A.: Grant support–Alcon Laboratories, Inc, Allergan, Santen Pharmaceutical Co, Ltd, Ellex, Ocular Therapeutix, Inc; Consulting fees–Alcon Laboratories, Inc, Allergan, Santen Pharmaceutical Co, Ltd, Pfizer, Merck Sharp & Dohme, Bausch & Lomb, Quark Pharmaceuticals; Travel support–Alcon Laboratories, Inc, Allergan, Santen Pharmaceutical Co, Ltd, Pfizer, Ellex. I.G.: Consultant and advisory board member–Alcon Laboratories, Inc, Allergan, ForSight, Merck, Pfizer; Speakers bureaus–Alcon Laboratories, Inc; Travel support–Alcon Laboratories, Inc, Pfizer. The other authors have no proprietary or commercial interest in any materials discussed in this article.
This study was funded by Alcon Laboratories, Inc , Fort Worth, Texas. Alcon participated in the design and conduct of the study, data management, data analysis, interpretation of the data, and preparation and approval of the manuscript.